Testing for sexually transmitted infections in women at risk for HIV
Part of Infections clinical trials.
This study tests if combining sexually transmitted infection (STI) testing with HIV prevention medication (PrEP) helps control the HIV epidemic. It is for sexually active women aged 15-39 who live in Rakai and recently participated in a community health survey.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a female between 15 and 39 years old.
- You are sexually active.
- You live in a Rakai community that is part of the Rakai Community Cohort Study.
- You took part in the most recent Rakai Community Cohort Study survey and agreed to have your blood samples stored and tested.
- You agreed to be contacted for future studies and are willing to be randomly assigned to one of the study groups.
- You can give your informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a program to help women at risk for HIV get PrEP, a medicine that prevents HIV. It focuses on women who may want to have a child or have been pregnant recently.
This study tests whether offering PrEP counseling to women with a recent STI at family planning clinics helps them start HIV prevention. Women who test positive for syphilis, gonorrhea, or chlamydia may be offered PrEP information and support.
This study helps transgender women who are not regularly using PrEP (a daily pill to prevent HIV) get access to HIV prevention services. It uses a smartphone to take pictures and connect with support.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study offers different forms of HIV prevention medicine (PrEP) to young women ages 18–30 who are visiting clinics for reproductive health services like family planning or postnatal care. It aims to see which delivery method works best for you.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.